 | Re-inventing Drug Development Subjects: Bioscience; Economics Finance Business & Industry; Physical Sciences; Pharmacology; Pharmaceutical Science; Business Management and Accounting; Chemistry; Drug Design & Development; Management - Pharmaceutical Science; Medicinal & Pharmaceutical Chemistry; Public & Nonprofit Management; The biopharmaceutical industry has entered an era of unprecedented change and challenge, characterized by increasing pricing pressures, rising rates of attrition in the product development lifecycle, and decreasing scientific innovation. The most successful products are losing patent protection, and pipelines have been unable to fill the gap. This Jeffrey S. Handen, PhD, is vice president of professional services with Medidata Solutions, Inc. Dr. Handen has published in multiple peer-reviewed and business journals, presented at numerous industry conferences and scientific meetings as an invited speaker, and served as past editor-in-chief of the Industrialization of Drug Discovery compendium. Before joining Medidata Solutions he was with Merck Research Laboratories for 6 years as a director of portfolio and project management helping to plan, manage, and execute Merck's clinical development portfolio. Prior to Merck, Dr. Handen held management consulting positions with Computer Science Corporation and IBM Business Consulting Services (formerly PricewaterhouseCoopers Consulting). With over 20 years of experience in pharmaceutical and biotechnology research and development, process reengineering, and systems and process implementation, Dr. Handen has also held research and management positions with the University of Pennsylvania and the National Institutes of Health. As vice president of professional services for Medidata Solutions, Dr. Handen is responsible for overseeing clinical development business process integration, solution architecting for optimizing clinical trials design execution and development, implementation of data-driven metrics, and developing and implementing operational metrics to improve clinical research processes. He holds a PhD in neurosciences from George Washington University as well as a BS from Duke University. |
